Cipla vs Apollohosp Q2 FY24

Cipla delivered a record quarter with revenue of ₹6,678 crore (+15% YoY) and EBITDA margin of 26%, driven by double-digit growth across India (+10%), North America (+28% to $229M), and South Africa (+12%). The India business benefited from a chronic mix shift (+140bps to 60%), while US growth was led by lanreotide (20% share) and albuterol share recovery. EBITDA guidance was raised to 23-24% (bias to higher end). Key upcoming catalysts include generic Symbicort filing in Q3, a peptide launch in Q4, and multiple complex filings in FY25. Risk: Indore facility OAI classification could delay US approvals.

Guidance read

EBITDA margin guidance raised to 23-24% for FY24: Management increased full-year EBITDA margin guidance from 23% to 23-24%, with bias towards the higher end. Generic Symbicort filing in Q3 FY24: Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies. Peptide product launch in Q4 FY24: One peptide product launch planned in Q4 FY24, with 3-4 more in FY25. US revenue sustainable range of $220-225M next quarter: Management guided US revenue of $220-225M as sustainable for the next quarter.

Risk read

Key risks include Indore facility OAI classification — Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.; Albuterol market share volatility — Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.; Revlimid volume uncertainty post-12-month period — Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Apollo Hospitals reported a robust Q2 FY24 with consolidated revenue of INR 4,847 crore (+14% YoY) and EBITDA of INR 628 crore (+11% YoY). Healthcare services revenue grew 12% to INR 2,547 crore, driven by 18% growth in insurance revenues (now 43% of IP revenue) and 20% growth in international patients. Occupancy stood at 68%, with ARPOB up 14% to INR 57,379. The pharmacy business grew 21% YoY, and Apollo 24|7 added 2 million new users, targeting operational breakeven by Q4 FY24. Management guided for 200 bps margin expansion in hospitals and 6%+ EBITDA margin for pharmacy. Key risks include delayed ramp-up of new bed additions and competitive intensity in metro markets.

Guidance read

Hospital EBITDA margin expansion of 200 bps: Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement. Pharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin: Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher. Apollo 24|7 operational breakeven in Q4 FY24: The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24. Addition of 2,300 beds over three years at INR 3,400 crore: Apollo plans to add 2,300 beds across eight locations over the next three financial years, with a capital outlay of INR 3,400 crore.

Risk read

Key risks include Delayed monsoon impacted medical admissions in South India — Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.; New hospital ramp-up may pressure near-term margins — Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.; Competitive intensity in metro markets — Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.